Noodle.ai and SMS digital Launch AI-Fueled Application for the Steel Industry
16.1.2020 17:00:00 EET | Business Wire | Press release
Leading Enterprise Artificial Intelligence® provider Noodle.ai and the digitalization team at SMS group, a trailblazer in digitalization for plant and equipment used in steel and nonferrous-metals production and processing, launched MPV today. MPV is the first joint AI-driven application for the steel industry. The launch follows the announcement of their partnership in June 2019.
As steel industry margins continue to shrink, one promising way for manufacturers to increase profitability is to pursue more advanced, high-strength steel production for applications such as automotive and electrical. However, production of these advanced steel grades requires much tighter control of the overall production process, which is impacted by numerous parameters across the mill.
The MPV (Mechanical Properties Variability) application utilizes artificial intelligence and machine learning to create a unique 'sense, predict, and recommend' framework that addresses challenges associated with the variability of mechanical properties in steel production. Mechanical properties include things such as yield strength, tensile strength, and elongation. The application senses patterns within mill data to fully understand the drivers of mechanical property variability. It then predicts when increased variability will occur and recommends the optimal input parameters, or PDI settings, required to optimize target mechanical properties such as yield strength, tensile strength, and elongation. As a result, the MPV application can help steel manufacturers achieve cost savings 3 ways: by reducing mechanical properties variability, reducing alloy costs due to better variability control, and minimizing out-of-spec production, which are sold as secondary grades or scrapped. One steel manufacturer using MPV is anticipating savings $2M per year.
“Our ability to deploy AI to produce steel with tighter tolerances allows us to address the requirements of high margin segments such as automotive and electrical, which immediately impacts our top line revenues in addition to the obvious cost savings,” said Denis Hennessy, Director of Product Development at Big River Steel, after implementing the MPV application.
In addition to addressing these challenges in mechanical properties variability, the AI and machine learning solutions that Noodle.ai and SMS digital have co-developed will also help steel manufacturers optimize product quality, asset availability and production efficiency. Together, Noodle.ai and SMS digital combine manufacturing equipment expertise, process modeling experience, and cutting-edge data science to accelerate time to value, enabling customers to quickly realize bottom-line impact.
“This partnership with SMS digital was created to make efficiency improvements that not only help steel manufacturers’ bottom line, but to rid the world of unnecessary industrial waste that often plagues this industry,” said Stephen Pratt, Founder and CEO, Noodle.ai. “We are encouraged by the results we’ve already seen with this application developed in partnership with SMS digital, and anticipate being able to assist an even larger list of steel manufacturers as we enter 2020 with MPV and the other applications we develop together.”
About Noodle.ai
Noodle.ai applies advanced data science to industries at the core of the global economy to create a world without waste. With Noodle.ai’s advanced Enterprise AI® applications, business leaders are empowered to make better decisions, reduce wasted energy, money, and resources, and ensure their businesses are built to last. Noodle.ai focuses on radical efficiency for supply chain and manufacturing using leading-edge artificial intelligence.
About SMS digital comprising SMS group Inc. Digital Solutions and SMS digital GmbH
SMS digital GmbH, the digital subsidiary of SMS group GmbH, and SMS group Inc. Digital Solutions collectively are a market leading supplier of digitalization for plant and equipment used in steel and NF-metals production and processing. SMS group GmbH generates worldwide sales totaling EUR 3.3 billion with more than 14,000 employees.
In close collaboration with its customers, SMS digital identifies and develops innovative products for the metals industry building on most advanced development techniques, in-depth metallurgical process knowhow and technological expert knowledge. SMS digital helps its customers make their plants and machines ready for the digital age by means of digital applications and the use of AI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005174/en/
Contact information
Leslie Poston, Noodle.ai
leslie.poston@noodle.ai
Thilo Sagermann, SMS group
thilo.sagermann@sms-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom